key: cord-0943069-7haa6owa
authors: Liu, Jen-Wei; Lin, Shen-Hua; Wang, Lin-Chien; Chiu, Hsiao-Yean; Lee, Jen-Ai
title: Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis
date: 2021-08-13
journal: JAMA Netw Open
DOI: 10.1001/jamanetworkopen.2021.19151
sha: 6d0fde27ad1acda69c9a9a264163b2e30e3b189a
doc_id: 943069
cord_uid: 7haa6owa

IMPORTANCE: Antiviral treatment of influenza is recommended for patients with influenza-like illness during periods of community cocirculation of influenza viruses and SARS-CoV-2; however, questions remain about which treatment is associated with the best outcomes and fewest adverse events. OBJECTIVE: To compare the efficacy and safety of neuraminidase inhibitors and the endonuclease inhibitor for the treatment of seasonal influenza among healthy adults and children. DATA SOURCES: Medline, Embase, and the Cochrane Register of Clinical Trials were searched from inception to January 2020 (the last search was updated in October 2020). STUDY SELECTION: Included studies were randomized clinical trials conducted among patients of all ages with influenza treated with neuraminidase inhibitors (ie, oseltamivir, peramivir, zanamivir, or laninamivir) or an endonuclease inhibitor (ie, baloxavir) compared with other active agents or placebo. DATA EXTRACTION AND SYNTHESIS: Two investigators identified studies and independently abstracted data. Frequentist network meta-analyses were performed; relative ranking of agents was conducted using P-score probabilities. Quality of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluations criteria. Data were analyzed in October 2020. MAIN OUTCOMES AND MEASURES: The time to alleviation of influenza symptoms (TTAS), complications of influenza, and adverse events (total adverse events, nausea, and vomiting). RESULTS: A total of 26 trials were identified that investigated antiviral drugs at high or low doses; these trials included 11 897 participants, among whom 6294 (52.9%) were men and the mean (SD) age was 32.5 (16.9) years. Of all treatments comparing with placebo in efficacy outcomes, high-quality evidence indicated that zanamivir was associated with the shortest TTAS (hazard ratio, 0.67; 95% CI, 0.58-0.77), while baloxavir was associated with the lowest risk of influenza-related complications (risk ratio [RR], 0.51; 95% CI, 0.32-0.80) based on moderate-quality evidence. In safety outcomes, baloxavir was associated with the lowest risk of total adverse events (RR, 0.84; 95% CI, 0.74-0.96) compared with placebo based on moderate-quality evidence. There was no strong evidence of associations with risk of nausea or vomiting among all comparisons, except for 75 mg oseltamivir, which was associated with greater occurrence of nausea (RR, 1.82; 95% CI, 1.38-2.41) and vomiting (RR, 1.88; 95% CI, 1.47-2.41). CONCLUSIONS AND RELEVANCE: In this systematic review and network meta-analysis, all 4 antiviral agents assessed were associated with shortening TTAS; zanamivir was associated with the shortest TTAS, and baloxavir was associated with reduced rate of influenza-related complications.

Overall, 2 trials were judged to have a low risk of bias across all domains. 2 trials were judged to have a high risk of bias for sequence generation and allocation concealment due to inadequate randomization and assignments. 5 trials were open-labeled and therefore judged to have a high risk of performance bias. Most studies were judged to have a low risk of bias for incomplete outcome data and selective reporting; however, 3 trials were judged to have a high risk of bias for incomplete outcome data, as drop-outs and loss to follow-up could have a clinically relevant impact on the intervention effect estimates. Effect sizes presented on the upper triangle are direct comparisons (head-to-head studies) between the row and columns; the effect sizes on the lower triangle are network meta-analyses between the column and the row. Comparisons are based on hazard ratio (95% confidence intervals) in TTAS and risk ratio (95% confidence intervals) in other outcomes. 

Imprecise (wide 95% CI)

Probable intransitivity due to different severity of illness (outpatients or hospitalized patients)

Incoherence between direct and indirect evidence (dominant estimate not similar to network estimate)

3. Studies failed to blind patients and investigators that might lead to performance bias. 4. Studies had inadequate randomization and assignments that might be anticipated. 5. Studies had incomplete outcome data given that drop-outs and people lost to follow-ups could have clinically relevant impact on the intervention effect estimates.